Recent data suggests that Cilgavimab, formerly known as COV2-2130, holds significant capability as a therapeutic agent for SARS-CoV-2 . This immunoglobulin exhibits a unique mechanism of function, specifically neutralizing the virus's ACE2-RBD with remarkable binding power. Initial trials suggest a robust capacity to prevent infection , possibly de